Arsenite slows S phase progression via inhibition of cdc25A dual specificity phosphatase gene transcription

Toxicological Sciences

Volumn 99, Issue 1, 2007, Pages 70-78

  Lehmann, Geniece M ^a   McCabe Jr , Michael J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Arsenite; cdc25A; Cell cycle; S phase inhibition; U937

Indexed keywords

ARSENITE SODIUM; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLOHEXIMIDE; DACTINOMYCIN; EPOXOMICIN; MESSENGER RNA; PROTEIN CDC25A; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL STRAIN U937; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEGRADATION; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PROTEIN DEPLETION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SUCROSE DENSITY GRADIENT CENTRIFUGATION; TRANSLATION INITIATION;

ARSENITES; CDC25 PHOSPHATASE; CYCLOHEXIMIDE; DACTINOMYCIN; DRUG COMBINATIONS; ENZYME INHIBITORS; HUMANS; MONOCYTES; PROTEIN SYNTHESIS INHIBITORS; RNA, MESSENGER; S PHASE; SODIUM COMPOUNDS; SULFHYDRYL REAGENTS; TRANSCRIPTION, GENETIC; U937 CELLS;

EID: 34547906448     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfm142     Document Type: Article

References (32)

1. Abraham, R. T. (2001). Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15, 2177-2196.
2. Allan, J. M., and Travis, L. B. (2005). Mechanisms of therapy-related carcinogenesis. Nat. Rev. Cancer 5, 943-955.
3. Antman, K. H. (2001). Introduction: The history of arsenic trioxide in cancer therapy. Oncologist 6(Suppl. 2), 1-2.
4. Begg, A. C., McNally, N. J., Shrieve, D. C., and Karcher, H. (1985). A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 6, 620-626.
5. Boutros, R., Dozier, C., and Ducommun, B. (2006). The when and wheres of CDC25 phosphatases. Curr. Opin. Cell Biol. 18, 185-191.
6. Brostrom, C. O., and Brostrom, M. A. (1998). Regulation of translational initiation during cellular responses to stress. Prog. Nucleic Acid Res. Mol. Biol. 58, 79-125.
7. Busino, L., Chiesa, M., Draetta, G. F., and Donzelli, M. (2004). Cdc25A phosphatase: Combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23, 2050-2056.
8. Cai, X., Shen, Y. L., Zhu, Q., Jia, P. M., Yu, Y., Zhou, L., Huang, Y., Zhang, J. W., Xiong, S. M., Chen, S. J., et al. (2000). Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14, 262-270.
9. Chen, F., Zhang, Z., Bower, J., Lu, Y., Leonard, S. S., Ding, M., Castranova, V., Piwnica-Worms, H., and Shi, X. (2002). Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 99, 1990-1995.
10. Chen, G. Q., Zhu, J., Shi, X. G., Ni, J. H., Zhong, H. J., Si, G. Y., Jin, X. L., Tang, W., Li, X. S., Xong, S. M., et al. (1996). In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88, 1052-1061.
11. Donzelli, M., and Draetta, G. F. (2003). Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 4, 671-677.
12. Donzelli, M., Squatrito, M., Ganoth, D., Hershko, A., Pagano, M., and Draetta, G. F. (2002). Dual mode of degradation of Cdc25 A phosphatase. EMBO J. 21, 4875-4884.
13. Galaktionov, K., Chen, X., and Beach, D. (1996). Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382, 511-517.
14. Gray, N. K., and Wickens, M. (1998). Control of translation initiation in animals. Annu. Rev. Cell Dev. Biol. 14, 399-458.
15. Kirkpatrick, D. S., Dale, K. V., Catania, J. M., and Gandolfi, A. J. (2003). Low-level arsenite causes accumulation of ubiquitinated proteins in rabbit renal cortical slices and HEK293 cells. Toxicol. Appl. Pharmacol. 186, 101-109.
16. McCabe, M. J., Jr., Singh, K. P., Reddy, S. A., Chelladurai, B., Pounds, J. G., Reiners, J. J., Jr., and States, J. C. (2000). Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase. J. Pharmacol. Exp. Ther. 295, 724-733.
17. McCollum, G., Keng, P. C., States, J. C., and McCabe, M. J., Jr (2005). Arsenite delays progression through each cell cycle phase and induces apoptosis following G2/M arrest in U937 myeloid leukemia cells. J. Pharmacol. Exp. Ther. 313, 877-887.
18. Meng, L., Mohan, R., Kwok, B. H., Elofsson, M., Sin, N., and Crews, C. M. (1999). Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. U.S.A. 96, 10403-10408.
19. Meyuhas, O., Bibrerman, Y., Pierandrei-Amaldi, P., and Amaldi, F. (1996). Isolation and analysis of polysomal RNA. In: A Laboratory Guide to RNA: Isolation, Analysis, and Synthesis (P. A. Krieg, Ed.), pp. 65-81. Wiley-Liss, Inc, New York.
20. Molinari, M., Mercurio, C., Dominguez, J., Goubin, F., and Draetta, G. F. (2000). Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep. 1, 71-79.
21. Noreault, T. L., Jacobs, J. M., Nichols, R. C., Trask, H. W., Wrighton, S. A., Sinclair, P. R., Evans, R. M., and Sinclair, J. F. (2005). Arsenite decreases CYP3A23 induction in cultured rat hepatocytes by transcriptional and translational mechanisms. Toxicol. Appl. Pharmacol 209, 174-182.
22. Park, W. H., Seol, J. G., Kim, E. S., Hyun, J. M., Jung, C. W., Lee, C. C. Kim, B. K., and Lee, Y. Y. (2000). Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 60, 3065-3071.
23. Sagata, N. (2002). Molecular biology. Untangling checkpoints. Science 298, 1905-1907.
24. Shen, Z. X, Chen, G. Q., Ni, J. H., Li, X. S., Xiong, S. M., Qiu, Q. Y., Zhu, J., Tang, W., Sun, G. L., Yang, K. Q., et al. (1997), Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89, 3354-3360.
25. Sherr, C. J. (2000). The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res. 60, 3689-3695.
26. Wang, Z.-G., Rivi, R., Delva, L., Konig, A., Scheinberg, D. A., Gambacorti-Passerini, C., Gabrilove, J. L., Warrell, R. P., Jr. and Pandolfi, P. P. (1998). Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92, 1497-1504.
27. Waxman, S., and Anderson, K. C. (2001). History of the development of arsenic derivatives in cancer therapy. Oncologist 6(Suppl. 2), 3-10.
28. Wegener, S., Hampe, W., Herrmann, D., and Schaller, H. C. (2000). Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur. J. Cell Biol. 79, 810-815.
29. White, R. J. (2001). Gene Transcription: Mechanisms and Control. Blackwell Publishers, Oxford.
30. Zhang, T. D., Chen, G. Q., Wang, Z. G., Wang, Z. Y., Chen, S. J., and Chen, Z. (2001). Arsenic trioxide, a therapeutic agent for APL. Oncogene 20, 7146-7153.
31. Zhao, H., Watkins, J. L., and Piwnica-Worms, H. (2002). Disruption of the check-point kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc. Natl. Acad. Sci. U.S A. 99, 14795-14800.
32. Zou, L., and Stillman, B. (1998). Formation of a preinitiation complex by S-phase cyclin CDK-dependent loading of Cdc45p onto chromatin. Science 280, 593-596.